AGXT and Duchenne muscular dystrophy: Myriocin, an inhibitor of SPT, strongly reduced the abundance of sphingolipid intermediates and reversed multiple DMD-associated, fundamental pathogenetic pathways, including aberrant Ca2+ homeostasis, compromised sarcolemmal membrane integrity, satellite cell imbalance, chronic inflammation, and fibrosis.